Hutchmed goes pivotal with HMPL-760 in B-cell lymphoma.
ApexOnco Front Page
Recent articles
Median PFS appears to back earlier response rate promise.
The company adds royalty aggregation to its R&D business.
And AbbVie and Genmab scoop their ASH presentation with new data.
But Enhertu is coming.
The restructured biotech’s new lead project enters phase 1.
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
The private biotech adds another asset to J&J’s prostate cancer pipeline.
